Collagenase Clostridium Histolyticum Market Size Forecast to Reach $891.34 Million by 2025

Collagenase Clostridium Histolyticum Market Overview
The Collagenase Clostridium Histolyticum Market size is forecast to reach $891.34 million by 2025, growing at a CAGR of 3.3% during the forecast period 2020-2025. Collagenase clostridium histolyticum is an enzyme that helps in treating dupuytren’s contracture by dismantling the collagen. This enzyme helps to break down the chord of thickened tissue and allows the straightening of fingers. Increasing usage of it in various medical areas such as wound care, necrotic tissue, burn management, and pain management are the major factors driving the growth of the market. Increasing research and development activities for the introduction of safer drugs and therapies is set to further enhance the overall market demand for the Collagenase Clostridium Histolyticum Market during the forecast period 2020-2025.

Key Takeaways
North America dominated the Collagenase Clostridium Histolyticum Market in 2019 owing to the high awareness among the population regarding diseases such as Peyronie’s and Dupuytren’s and their medications. The Collagenase Clostridium Histolyticum Market scope for different regions will be provided in the final report.
Increasing adaptive rate of the medications and disease awareness along with the increasing focus on discovering other usages of collagenase in human healthcare is likely to aid in the market growth of the Collagenase Clostridium Histolyticum Market.
Detailed analysis of the Strength, Weakness, and Opportunities of the prominent players operating in the market will be provided in the Collagenase Clostridium Histolyticum Market report.
The presence of a stringent regulatory approval framework and high prices of collagenase is set to create hurdles for the Collagenase Clostridium Histolyticum Market.

Collagenase Clostridium Histolyticum Market Segment Analysis – By Type of Medications
The XIAFLEZ segment held the largest share in the Collagenase Clostridium Histolyticum Market in 2019 and is estimated to grow at a CAGR of 4.9% during the forecast period. XIAFLEZ medication is used to treat certain conditions (Dupuytren’s contracture, Peyronie’s disease) that are caused by a certain protein (collagen) in the body. Receiving an injection of XIAFLEX cause damage to the tubes in the penis called the corpora. After treatment with XIAFLEX , one of these tubes break during an erection which is called a corporal rupture or penile fracture. This could require surgery to fix the damaged area. Collagenase Santyl Ointment is a sterile enzymatic debriding ointment that contains 250 collagenase units per gram of white petrolatum USP. The enzyme collagenase is derived from the fermentation by Clostridium histolyticum and possesses the unique ability to digest collagen in necrotic tissue. The XIAFLEZ is set to be the highest growing segment and is estimated to register the highest CAGR during the forecast period 2020-2025.

Collagenase Clostridium Histolyticum Market Segment Analysis – By Type of Disease
The Dupuytren’s Contracture segment held the largest share in the Collagenase Clostridium Histolyticum Market in 2019. Dupuytren’s contracture is a condition in which one or more fingers become permanently bent in a flexed position. It usually begins as small, hard nodules just under the skin of the palm, then worsens over time until the fingers can no longer be straightened. Risk factors include family history, alcoholism, smoking, thyroid problems, liver disease, diabetes, previous hand trauma, and epilepsy. The underlying mechanism involves the formation of abnormal connective tissue within the palmar fascia. Peyronie’s disease is a noncancerous condition resulting from fibrous scar tissue that develops on the penis and causes curved, painful erections. The Dupuytren’s Contracture is set to be the highest growing segment and is estimated to register the highest CAGR during the forecast period 2020-2025.

Collagenase Clostridium Histolyticum Market Segment Analysis – By Geography
North America dominated the Collagenase Clostridium Histolyticum Market in 2019 with a share of more than 40.2%, followed by the Europe owing to the high awareness among the population regarding the diseases such as Peyronie’s and Dupuytren’s and their medication. Rapid clinical advancements are also increasing the growth of the collagenase clostridium histolyticum market in this region.
However, Europe is estimated to grow at a higher CAGR during the forecast period 2020-2025 owing to the rising prevalence of Dupuytren’s disease. The presence of advanced healthcare infrastructure is also increasing the growth of the collagenase clostridium histolyticum market in this region.

Collagenase Clostridium Histolyticum Market Drivers
Increasing awareness among the population regarding diseases such as Dupuytren’s and their medications
Increasing awareness among the population regarding diseases such as Dupuytren’s and their medications is increasing the growth of the Collagenase Clostridium Histolyticum Market. Dupuytren’s disease, also called Dupuytren’s contracture or palmar fibromatosis, is a condition in which the connective tissue under the skin of the palm contracts and toughens over time. The fibroproliferative disorder affects the palmar fascia; ropelike collagen cords form, thicken, and shorten, causing permanent flexion contractures of joints and progressive flexion of one or more fingers. Dupuytren’s disease usually presents in one hand first, and at some later time might appear in the other hand. Thickening of the lines in the palms of the hands or on knuckles and skin pitting and dimpling might also be present. There is an increase in awareness among the population regarding the disease. Thus, increasing the growth of the Collagenase Clostridium Histolyticum Market during the forecast period 2020-2025.

Increasing the adaptive rate of the medications and disease awareness along with the increasing focus on discovering other usages of collagenase in human healthcare
The increasing adaptive rate of the medications and disease awareness along with the increasing focus on discovering other usages of collagenase in human healthcare is increasing the growth of the Collagenase Clostridium Histolyticum Market. Collagenase clostridium histolyticum is an enzyme produced by the bacterium Clostridium histolyticum that dismantles collagen. It is used as a powder-and-solvent injection kit for the treatment of dupuytren’s contracture, a condition where the fingers bend towards the palm and cannot be fully straightened, and Peyronie’s disease, a connective tissue disorder involving the growth of fibrous plaques in the soft tissue of the penis. The proteolytic processing of collagen (collagenolysis) is critical in development and homeostasis but also contributes to numerous pathologies.With the increasing number of patients suffering from these disease, there is an increase in the adaptive rate of the medicine and people are also getting awared about the disease.Thus, increasing the growth of the Collagenase Clostridium Histolyticum Market during the forecast period 2020-2025.

Collagenase Clostridium Histolyticum Market Challenges
Presence of stringent regulatory approval framework and high prices of collagenase
Some of the factors that can impede the growth of the Collagenase Clostridium Histolyticum Market are presence of stringent regulatory approval framework and high prices of collagenase.

Collagenase Clostridium Histolyticum Market Industry Outlook
Product launches, mergers and acquisitions, joint ventures, and R&D activities are key strategies adopted by players in the Collagenase Clostridium Histolyticum Market. In 2019, the Collagenase Clostridium Histolyticum Market share is consolidated by the top ten players present in the market. Collagenase Clostridium Histolyticum Market, the top 10 companies are Healthpoint Ltd., BioSpecifics Technologies Corp, Auxilium Pharmaceuticals Inc., Actelion Pharmaceuticals Canada Inc., Smith & Nephew PLC, Advanced Biofactures Corporation, Swedish Orphan Biovitrum AB, Endo Pharmaceuticals Inc., Asahi Kasei Corporation, and Beijing Solarbio Science & Technology among others.

Acquisitions/Product Launches
In May 2015, Endo Pharmaceuticals Inc., a highly focused generics and specialty branded pharmaceutical company delivering quality medicines to patients in need through excellence in development, manufacturing and commercialization acquired Par Pharmaceuticals.